Published in Clinical Oncology Week, April 10th, 2006
Frohlich, a urologic oncologist with over a decade of oncology drug development and patient treatment experience in the public and private sectors, will focus on the completion of the clinical section of the Biologics License Application (BLA) for PROVENGE, which the company is on track to submit to the U.S. Food and Drug Administration (FDA) by the middle of this year and the ongoing Phase 3 IMPACT (D9902B) clinical study of PROVENGE in men with advanced prostate cancer.
Prior to joining Dendreon, Frohlich was vice president and medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week